Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.

TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.

First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.

Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.

GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.